Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeREGNRegeneron Pharmaceuticals$584.74+0.9%$575.71$476.49▼$959.60$61.98B0.311.10 million shs691,021 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceREGNRegeneron Pharmaceuticals+0.45%+1.18%-2.14%+1.21%-40.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeREGNRegeneron Pharmaceuticals$584.74+0.9%$575.71$476.49▼$959.60$61.98B0.311.10 million shs691,021 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceREGNRegeneron Pharmaceuticals+0.45%+1.18%-2.14%+1.21%-40.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceREGNRegeneron Pharmaceuticals 2.79Moderate Buy$817.8839.87% UpsideCurrent Analyst Ratings BreakdownLatest REGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025REGNRegeneron PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$850.0010/13/2025REGNRegeneron PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$650.00 ➝ $660.0010/10/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$761.00 ➝ $756.0010/8/2025REGNRegeneron PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025REGNRegeneron PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/2/2025REGNRegeneron PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy8/27/2025REGNRegeneron PharmaceuticalsSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$753.00 ➝ $781.008/27/2025REGNRegeneron PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$813.00 ➝ $831.008/14/2025REGNRegeneron PharmaceuticalsRedburn AtlanticSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/14/2025REGNRegeneron PharmaceuticalsRothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$890.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookREGNRegeneron Pharmaceuticals$14.20B4.36$46.33 per share12.62$268.50 per share2.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateREGNRegeneron Pharmaceuticals$4.41B$39.6814.7415.381.8031.37%15.06%11.77%10/28/2025 (Estimated)Latest REGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/28/2025Q3 2025REGNRegeneron Pharmaceuticals$9.73N/AN/AN/A$3.57 billionN/A8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.43$12.89+$4.46$12.81$3.30 billion$3.68 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthREGNRegeneron Pharmaceuticals$3.520.60%N/A8.87%N/ALatest REGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/1/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%8/18/20258/18/20259/3/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioREGNRegeneron Pharmaceuticals0.094.603.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipREGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipREGNRegeneron Pharmaceuticals7.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableREGNRegeneron Pharmaceuticals15,106105.99 million98.55 millionOptionableREGN HeadlinesRecent News About These CompaniesARK Investment Management LLC Sells 1,088 Shares of Regeneron Pharmaceuticals, Inc. $REGNOctober 22 at 9:13 AM | marketbeat.comPrivate Capital Advisors Inc. Takes $323,000 Position in Regeneron Pharmaceuticals, Inc. $REGNOctober 22 at 7:06 AM | marketbeat.comImmuno-Oncology Stocks Q2 Recap: Benchmarking Exact Sciences (NASDAQ:EXAS)October 22 at 4:04 AM | finance.yahoo.comEarnings Preview: Regeneron (REGN) Q3 Earnings Expected to DeclineOctober 21 at 11:06 AM | zacks.comHere's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth TodayOctober 21 at 8:00 AM | benzinga.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by DekaBank Deutsche GirozentraleOctober 21 at 5:29 AM | marketbeat.comRegeneron Pharmaceuticals (REGN) to Release Quarterly Earnings on TuesdayOctober 21 at 4:57 AM | marketbeat.comVIRGINIA RETIREMENT SYSTEMS ET Al Invests $27.85 Million in Regeneron Pharmaceuticals, Inc. $REGNOctober 20 at 5:16 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by John G Ullman & Associates Inc.October 19 at 6:13 AM | marketbeat.comNordea Investment Management AB Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGNOctober 19 at 4:39 AM | marketbeat.comAxxcess Wealth Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGNOctober 19 at 4:02 AM | marketbeat.comCatawba River Capital Purchases 20,006 Shares of Regeneron Pharmaceuticals, Inc. $REGNOctober 18, 2025 | marketbeat.comArnhold LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGNOctober 18, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Sells 6,577 Shares of Regeneron Pharmaceuticals, Inc. $REGNOctober 18, 2025 | marketbeat.comIs FDA and EMA Progress for Libtayo Transforming the Investment Story for Regeneron (REGN)?October 17, 2025 | finance.yahoo.comLibtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and RadiationOctober 17, 2025 | globenewswire.comRegeneron Pharmaceuticals, Inc. $REGN Stock Holdings Trimmed by Chevy Chase Trust Holdings LLCOctober 17, 2025 | marketbeat.comApplied Finance Capital Management LLC Acquires 3,190 Shares of Regeneron Pharmaceuticals, Inc. $REGNOctober 17, 2025 | marketbeat.comPraxis Investment Management Inc. Has $1.59 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGNOctober 17, 2025 | marketbeat.comNew York State Teachers Retirement System Has $45.98 Million Stake in Regeneron Pharmaceuticals, Inc. $REGNOctober 17, 2025 | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Concurrent Investment Advisors LLCOctober 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREGN Company DescriptionsRegeneron Pharmaceuticals NASDAQ:REGN$584.74 +5.40 (+0.93%) Closing price 04:00 PM EasternExtended Trading$586.69 +1.95 (+0.33%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
